CA2390281C - Hematopoietic differentiation of human embryonic stem cells - Google Patents
Hematopoietic differentiation of human embryonic stem cells Download PDFInfo
- Publication number
- CA2390281C CA2390281C CA002390281A CA2390281A CA2390281C CA 2390281 C CA2390281 C CA 2390281C CA 002390281 A CA002390281 A CA 002390281A CA 2390281 A CA2390281 A CA 2390281A CA 2390281 C CA2390281 C CA 2390281C
- Authority
- CA
- Canada
- Prior art keywords
- cells
- hematopoietic
- human
- embryonic stem
- medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1394—Bone marrow stromal cells; whole marrow
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
Abstract
Disclosed herein are methods of obtaining human hematopoietic cells from human embryonic stem cells using mammalian stromal cells. Hematopoietic cells derived in this way are useful for creating cell cultures suitable for transplantation, transfusion, and other purposes.
Description
WO 01/34776 ~ ~ PCT/US00/23469 HEMATOPOIETIC DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS
CROSS REFERENCES TO RELATED APPLICATIONS
Not applicable.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
__ __ BACKGROUND OF THE INVENTION
The present invention relates to the use of human embryonic stem cells to create blood-related cells, and the use of those blood-related cells for various purposes.
Techniques for isolating stable cultures of human embryonic stem cells have recently been described by our laboratory. See U.S. patent 5,843,780 and J. Thomson et al., 282 Science 1145-1147 (1998).
We have deposited two of our human embryonic stem cell lines with the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20170-2209 U.S.A. on July 7, 1999 and July 15, 1999 respectively.
Taxonomic descriptions of these deposits are human embryonic stem cell lines H1 and H9 respectively. It has been proposed in these publications that such cell lines may be used for, among other things, providing a source of specified cell lines of various types for research, transplantation and other purposes.
Under the storage and culturing conditions described in these publications the cell lines are maintained long term without differentiation into specific cell types.
When the cell lines are subsequently injected into immunodeficient mice, they form teratomas demonstrating differentiation into multiple tissue types.
When ES cells are used to produce desired cells, it is often preferable to optimize differentiation towards specific cell types. In the case of hematopoietic cells it is desirable that this result in hematopoietic cells that can be isolated and used to form multiple hematopoietic lineages. These cells may include, but not be limited to, hematopoietic stem cells.
Hematopoietic stem cell populations have been isolated directly from bone marrow. See C. Baum et al.
89 PNAS USA 2804-2808 (1992). However, this relies on a supply of bone marrow to obtain the cells.
There have also been some attempts to direct murine embryonic cell populations towards hematopoietic cells.
See e'a. U.S. patent 5,914,268; G. Keller, 7 Current Opinion In Cell Biology, 862-869 (1995); and T. Nakano et al. 265 Science 1098-1101 (1994). See also M. Weiss, 11 Aplastic Anemia And Stem Cell Biology, 1185-1195 (1997);
and S. Morrison et al., 11 Annu. Rev. Cell Dev. Biol., 35-71 (1995).
However, applying these teachings to primates has proven difficult. For example, in F. Li et al., 92 Blood 368a (1998) there was a discussion of techniques for differentiation of rhesus embryonic stem cell lines using a stromal cell line and exogenous cytokines. However, that group has more recently reported that their techniques had inadequate formation of colonies.
The treatment of various diseases by tissue transplantation has become routine. However, there can be waiting lists to obtain natural donated organs, cells, or tissue. Even when the natural donor material becomes available there is often a problem with rejection.
Traditional approaches for suppressing an immune response of recipients have drawbacks. For example, immunosuppressive drugs are costly and often have side effects.
In WO 98/07841 there was discussed techniques of deriving embryonic stem cells that are MHC compatible with a selected donor (e. g. transplanting a donor nucleus into an enucleated oocyte, followed by derivation of the stem cells therefrom). The application suggested that the resulting cells could be used to obtain MHC
compatible hematopoietic stem cells for use in medical treatments requiring bone marrow transplantation.
However, some diseases such as type 1 diabetes mellitus or multiple sclerosis involve an autoimmune response. For example, merely transplanting pancreatic islets (which are MHC compatible to the diseased individual) to replace destroyed pancreatic islets will not provide sufficient long term reduction in type 1 diabetes mellitus, as the immune system of the host will still attack the transplanted islets.
It can therefore be seen that a need exists for techniques for causing human embryonic stem cell cultures to differentiate to desired hematopoietic colonies.
Further, it is desired to develop improved uses for hematopoietic cells.
BRIEF SUMMARY OF THE INVENTION
In one aspect the present invention provides a method for obtaining human hematopoietic cells. One exposes a human embryonic stem cell culture to mammalian hematopoietic stromal cells so as to thereby create human hematopoietic cells. At least some of the human hematopoietic cells that are so created are CD34+ and/or are capable of forming hematopoietic cell colony forming units in methylcellulose culture.
CD34 is a standard marker for hematopoietic stem cells, as described in C. Baum et al. 89 PNAS USA 2809-2808 (1992) and S. Morrison et al., 11 Annu. Rev. Cell Dev. Biol., 35-71 (1995). The property of capability of forming a colony forming unit is indicative that the cells have the desired characteristics to form more differentiated hematopoietic lineages.
The stromal cells are preferably derived from bone marrow cells or embryonic yolk sac cells. Murine stromal cells may be used for this purpose. However, primate WO 01/34776 CA 02390281 2002-05-03 pCT/US00/23469 stromal and other mammalian stromal cells should be suitable as well.
In another aspect the invention provides a human hematopoietic cell which was derived from a human embryonic stem cell culture in vitro, and is capable of forming hematopoietic cell colony forming units in methylcellulose culture. As used in this patent, the term "derived" is intended to mean obtained directly or indirectly (e.g. through one or more intermediates or passages).
In yet another aspect the invention provides a method of transplanting human cellular material into a human recipient host. One obtains human hematopoietic cells which have been derived in vitro from an embryonic stem cell culture. One then obtains a selected human cellular material other than hematopoietic cells, the selected non-hematopoietic material having major histocompatibility complex compatibility to the hematopoietic cells. One then transplants both the hematopoietic cells and selected human non-hematopoietic cellular material into the human host.
For example, one can obtain human hematopoietic cells which have been derived in vitro from an embryonic stem cell culture (e. g. using the techniques described below). One also obtains human pancreatic islets which have MHC compatibility to the hematopoietic cells. Both the hematopoietic cells and pancreatic islets are then transplanted into the human (preferably after the recipient's own bone marrow has been inactivated).
The pancreatic islets can be obtained directly from a donor whose cells were used to create the embryonic stem cell culture. Alternatively, a single embryonic stem cell culture can be differentiated along two different paths. In one process the above technique can be used to create hematopoietic stem cells. These cells should develop into multiple hematopoietic lineages when WO 01/34776 CA 02390281 2002-05-03 pCT/US00/23469 transplanted into appropriate hosts. These lineages should include lymphocytes which would be tolerant of other cells derived from the same parental embryonic stem cells. In another process the stem cells would be directed towards pancreatic islets.
In another example one could supply oligodendrocytes to a human who has a multiple sclerosis condition. One obtains human hematopoietic cells which have been derived in vitro from an embryonic stem cell culture (e. g. using a technique described below). One also obtains human oligodendrocytes which have MHC compatibility to the bone marrow cells and transplants both the bone marrow cells and oligodendrocytes into the human.
The same human whose genetic material was used to create the embryonic stem cell can be a donor for the oligodendrocytes. Alternatively, the same embryonic stem cell culture can be differentiated along two separate paths to provide the two transplantable materials.
With respect to either disease (and potentially other autoimmune diseases) the immune and autoimmune rejection problems should be reduced by this technique.
In this regard, the recipient's original bone marrow can be totally or partially inactivated by radiation or chemical means before the transplantation. Thereafter, it is replaced at least in part by the transplanted hematopoietic cells. The elimination/reduction of the original bone marrow reduces the body's ability to create an autoimmune response. The matching of the MHC of the replacement bone marrow and the second transplantable material insures that the second material won't be rejected by the transplanted bone marrow.
Moreover, co-transplantation of hematopoietic cells and other tissue can be done to promote acceptance of the second tissue (e. g. heart muscle plus hematopoietic cells for treating heart disease; hepatocytes plus hematopoietic cells for treating liver disease). By creating hematopoietic chimeras improved acceptance of tissues with similarly matched MHC type can be obtained.
The present invention should be suitable to obtain a wide variety of hematopoietic cells of interest, such as erythroid cells, granulocyte cells, macrophages, lymphocyte precursors, monocytes, B cells, T cells, and the like. In this regard, colonies of differentiated ES
cells develop into hematopoietic colonies when harvested, separated into single cells, and plated into appropriate cultures. These colonies demonstrate the development of colony-forming cells which proliferate into colony-forming units (including colony forming unit-erythroid (CFU-E), blast forming unit-eythroid (BFU-E), colony forming unit-macrophage (CFU-M), colony forming unit-granulocyte/macrophage (CFU-GM) and colony forming unit-high proliferative potential (CFU-HPP)). The identification of colony forming cells indicates the differentiation of embryonic stem cells into hematopoietic cells capable of expanding into defined hematopoietic lineages under defined conditions.
The objects of the present invention therefore include providing:
(a) methods of the above kind for obtaining hematopoietic cells;
(b) cells derived using those methods; and (c) methods for using those derived cells for transplantation, transfusion and other purposes.
These and still other objects and advantages of the present invention will be apparent from the description of the preferred embodiments that follows. However, the claims should be looked to in order to judge the full scope of the invention.
DETAILED DESCRIPTION
Embryonic Stem Cell Culture The previously described human ES cell line Hl was used for the majority of experiments, albeit some of the WO 01/34776 CA 02390281 2002-05-03 pCT/US00/23469 following studies were done with the previously described ES cell lines H9 (or H9.2) with similar results. These cells were removed from frozen (liquid nitrogen) stocks of cells derived from the original isolated and propagated cell line. The Hl ES cells were grown in 6 well culture dishes (Nunclon, Fisher).
The dish was first coated with O.lo gelatin solution (Sigma) for one or more days in a 37°C/5o CO~ incubator.
After the one or more days, the gelatin solution was removed and the wells of the plate were next coated with irradiated mouse embryonic fibroblast (MEF) cells. MEF
cells were derived from day 12-13 mouse embryos in medium consisting of DMEM (GibcoBRL) supplemented with loo fetal bovine serum (Hyclone or Harlan), 2 mM 1-glutamine (GibcoBRL), and 100 units/ml. Penicillin, 100 mg/ml streptomycin (Sigma).
The MEF cells were irradiated with 5500 cGy from a cesium source prior to plating in the wells. The MEFs were added at a density of 5 x lO4cells/ml, 2.5 ml/well.
The plate coated with MEFs was then placed in 37°C/5o CO2 incubator for one or more days until addition of ES
cells.
ES cells were passed onto new MEFs at approximately 5-8 day intervals. The time depends on cell density and morphologic appearance of differentiation. For passage, the medium in a well of ES cells was removed and 1-2 ml of medium containing 1 mg/ml collagenase IV in DMEM
(GibcoBRL) was added. The plate was then placed at 37°C/5o CO2 for 5-20 minutes until the colonies of ES
cells began to round up.
The well was then scraped with a 5 ml pipette to detach the ES cells from the plate. The contents of the harvested well were placed in a 15 ml conical tube (Fisher) and spun in a centrifuge at 1000 rpm for 5 minutes. The medium was removed and 10 ml of fresh medium was added. This ES cell medium consists of F12/DMEM
_7_ (GibcoBRL)) supplemented with 20o serum replacement medium (GibcoBRL), 8 ng/ml of bFGF (GibcoBRL), 1o non-essential amino acid solution (GibcoBRL), 1 mM 1-glutamine (GibcoBRL), and 0.1M (3-mercaptoethanol.
The cells were again spun (5 min/1000 rpm), medium removed and resuspended at a concentration of 2.5 ml of medium for each (typically 15 ml medium for plating into 6 new wells, this would be a 1:6 passage). The cells were then pipetted into the wells of a plate that had been previously coated with MEFs as described above. The cells were evenly distributed into each well and the plate was placed in an incubator at 37°C/5o CO2.
At times if there were colonies of ES cells showing morphologic appearance of differentiation prior to cell passage, these colonies were removed by gentle scraping with a pulled glass pipette. This was done with observation through a dissecting microscope. After removal of the differentiated cells, the remaining colonies were passaged as above.
After passage, each well of ES cells was "fed" with fresh medium at 24-48 hour intervals. Here, the medium of each well was removed and 2.5 ml of fresh ES medium was added. All feeding and passage of ES cells were done in a sterile environment.
Differentiation Of ES Cells To promote hematopoietic differentiation of the human ES cells, the ES cells were harvested as above. The cells were then plated in 6 well plates coated with a mammalian stromal cell. In one experiment we used C166 cells that were previously irradiated with 2500 cGy. The C166 cells were originally obtained from the yolk sac of mice at embryonic day 12 and were graciously provided by Dr. Robert Auerbach (UW-Madison).
In another experiment, S17 cells were used. They were originally obtained from mouse bone marrow, and were -g-graciously provided by Dr. Kenneth Dorshkind (then at UC-Riverside, now at UCLA).
The C166 or S17 cells were plated at a density of 1 x 10'' cells/ml, 2.5 ml/well. The ES cells plated onto either S17 of C166 cells were then allowed to grow in a medium consisting of DMEM (GibcoBRL) supplemented with 20o fetal bovine serum (Hyclone), to nonessential amino acid solution, O.1M (3-mercaptoethanol, and 1 mM 1-glutamine. This medium was replaced in each well at 24-72 hour intervals with fresh medium. In selecting an appropriate medium, one merely needs to provide conventional conditions for cell growth, albeit supplemented with the specified stromal cells.
After 3-7 days from plating onto S17 or C166 cells, the ES cells began to visually appear differentiated in that they did not have the same uniform appearance as the undifferentiated ES cells maintained on MEF feeder cells.
The colonies of ES cells began to form multiple different cell types. Some of these colonies had regions that appeared to consist of cells with a cobblestone morphology indicative of colonies of early hematopoietic progenitor cells.
Confirming Blood-Related Cells One method to determine the presence of appropriate hematopoietic cells is to assay for hematopoietic colony forming cells (CFCs) in semisolid methylcellulose-containing medium. Here, the ES cells were allowed to differentiate on either C166 or S17 cells for 2-3 weeks, maintained as described above. After this time the medium was removed. 2.5 ml of calcium and magnesium free phosphate buffered saline (PBS) was added for 2-5 minutes, removed, and 1.5 ml. of trypsin (0.125x)-EDTA
(1mM) medium was added.
The cells were then placed at 37°C/5o C02 for 10 minutes. After this time, the colonies began to disassociate. The cells were further disassociated by _g_ pipetting and scraping the wells. The cells were placed in a 15 ml. conical, spun 5 min/1000 rpm, medium removed and 10 ml fresh medium (DMEM + 10 o FBS + 1-glutamine+
pen/strep) was added, and spun again. The cells were then suspended in 5 ml medium and passaged through a 100 mM
nytex filter to remove clumps of cells.
The filter was washed with an additional 5 ml medium. The disassociated/filtered cells were then counted on a hemacytometer and 1 x 10~ (usually, but not always this many cells) cells were placed in a new 15 ml conical. These cells were then spun, medium removed and 5 ml medium consisting of IMDM (GibcoBRL) supplemented with 2o fetal bovine serum (Hyclone) was added. Cells were spun, medium removed and 250 ul medium (IMDM + 2o FBS) was added.
In accordance with the specified test conditions, these cells were then added to 2.5 ml of Methocult GF+
H4435 medium (StemCell Technologies). This medium consists of l.Oo methylcellulose, supplemented with 300 FBS, 20 ng/ml IL-3, 20 ng/ml IL-6, 50 ng/ml stem cell factor, 3 units/ml erythropoietin, 20 ng/ml GM-CSF, 20 ng/ml G-CSF, 2 mM 1-glutamine, O.lmM b-mercaptoethanol, 1% bovine serum albumin. The cells in methylcellulose were then vortexed vigorously and then 1.1 ml of the mixture was plated onto a P35 plastic dish (Stem Cell Technologies), spread evenly on the dish and placed at 37°C/5% CO,.
Duplicate plates of each sample were typically plated with 4 x 10' cells/plate. After 14-21 days, the plates were analyzed under a microscope for the presence of hematopoietic colonies. The colonies were identified by comparison to a colony atlas (StemCell Technologies) or the book: Culture of Hematopoietic Cells, RI Freshney, IB Pragnell, MG Freshney, eds., Wiley-Liss, Inc. 1994.
Colonies were identified as one of the following: colony forming unit-erythroid (CFU-E), blast forming unit-WO 01/34776 CA 02390281 2002-05-03 pCT/US00/23469 eythroid (BFU-E), colony forming unit-macrophage (CFU-M), colony forming unit-granulocyte/macrophage (CFU-GM) or colony forming unit-high proliferative potential (CFU-HPP) .
The presence of the desired hematopoietic cells can also be confirmed by flow cytometry. One can look for specified cell surface antigens by flow cytometry. Here, ES cells differentiated on S17 cells or C166 cells as described above for 14-21 days, were harvested with trypsin/EDTA as described above and passed through a 100 mM nytex filter. The filtered cells were counted on a hemacytometer, then aliquotted into 15 X 75 plastic tubes (Fisher) at approximately 1 x 105 cells/tube. The cells were then spun, medium removed and 2-3 ml of FACS medium was added. (FRCS medium is PBS with O.So BSA (Sigma), O.lo sodium azide (Sigma)).
The cells were again spun and medium removed. Next an antibody directly linked to a fluorescent marker (FITC
or PE) was added to the wells at a concentration as recommended by the supplier. Cells have been analyzed with the following antibodies: CD34-FITC (Immunotech), CD45-PE (Pharmingen). IgG1-FITC and IgGl-PE were used as isotype controls for non-specific staining of the cells.
Cells were incubated with the appropriate antibody for approximately 30 min on ice, washed 1-2 times with 2-3 ml FAGS medium and resuspended in approximately 0.5 ml FRCS
medium.
The antibody labeled cells were then analyzed using a FACScan (Becton Dickinson) as per manufacturers recommendations. The presence of dead cells was determined by addition of propidium iodide (1 mg/ml solution, 5 ul added per tube) or 7-AAD (Calbiochem) (0.2 mg/ml ,5 ul/tube). The software for analysis was eithe r PC Lysis or Cellquest.
The following experimental techniques were used to analyze antigen expression by immunohistochemistry (IHC).
WO 01/34776 CA 02390281 2002-05-03 pCT~S00/23469 Here, differentiated ES cells that have been co-cultured with either C166 or S17 as above, were harvested with trypsin/EDTA as above. The cells were resuspended in medium containing DMEM supplemented with loo FBS at a concentration of approximately 1 x 109 - 1 x 10'.
"Cytospin" preparations of these cells were then made by spinning 1 x 10=~ - 1x 104 cells onto a glass slide (Superfrost/plus, Fisher) with a Cytospin II centrifuge (Shanndon).
These slides were then fixed with cold acetone and stored frozen at -20°C. For IHC staining the slides were thawed at room temperature and the cell pellet was outlined with a wax pen (DAKO). The cells were then stained as follows using a Vectastain ABC kit (Vector Laboratories, Burlingame, CA), all incubations were at room temperature. 100-200 ul PBS was added onto the cells for 5 minutes then removed. Vectastain blocking antibody solution (horse serum) was then added onto the cells for 15 minutes. The cells were then blotted dry and 100-200 ul of primary antibody solution was added. The primary antibodies were: IgGl (1 ug/sample, Sigma), anti-CD34 (0.5 ug/sample, Immunotech), anti-CD45 (1 ug/sample, DAKO), anti-class I (1 ug/sample, gift from Dr. Paul Leibson, Mayo Clinic), anti-CD14 (1 ug/sample, Pharmingen), anti-CD31 (1 ug/sample, Pharmingen).
Primary antibody was added for 30 minutes followed by PBS for 10 minutes. Next, biotinylated anti-IgG
antibody was added (Vectastain kit, solution B) for 30 minutes followed by PBS for 10 minutes. Next Vectastain ABC solution was added for 30 minutes at room temperature followed by PBS for 10 minutes. Next DAB solution (Vectastain) was added for 5 minutes followed by washing under running tap water for 10 minutes. In some experiments, the slides were then counterstained with Gill's hematoxylline solution (Vector labs) for 3 minutes followed by washing with running tap water for 10 minutes. The slides were then air dried. Cells staining positive appear brown.
CD34+ was demonstrated within a mixed population of cells (about lo) after 2-3 weeks. Even more importantly, differentiated ES cells were shown to develop into hematopoietic colonies when harvested, separated into cells and plated into methylcellulose (semi-solid) cultures.
Transplantation Currently hematopoietic cell transplantation is conducted clinically primarily for patients who have received high dose chemotherapy for treatment of malignancies. These patients typically receive a heterogeneous mixture of hematopoietic cells either from an autologous or allogeneic source. Human ES-derived hematopoietic stem cells will at minimum provide a more homogeneous cell population for hematopoietic cell transplantation.
Further, as discussed above, the MHC characteristics of the transplantation can now be controlled, thereby enabling treatment of autoimmune diseases. For example, both hematopoietic stem cells (HSCs) and a second lineage (e. g. pancreatic islets for diabetes or oligodendrocytes for multiple sclerosis) could be derived from the same parental ES cell line. With both lineages available, a hematopoietic chimera could be first created by performing a fully allogeneic hematopoietic cell transplant (HCT). The established state of chimerism would allow the recipient's immune system to "see" the subsequent transplant of the second cell type (e. g.
pancreatic islets cell or oligodendrocyte) as "self" and should not be rejected.
Note for example that oligodendrocytes have been obtained from mouse ES cells (O. Brustle et al., 285 Science 754-6 (1999)), as have cardiac muscle cells (M.
Klug et al., 98 J. Clin. Invest. 216-224 (1996)).
This method of creating hematopoietic chimeras will also promote acceptance of tissues transplanted for reasons other than autoimmunity. In this regard, mice receiving allogeneic hematopoietic stem cells do not reject other tissues with the same genetic background as the hematopoietic cells, but will still reject third-party grafts. See K. Gandy et al., 65 Transplantation 295-304 (1998).
In addition to animal studies, there are now clinical case reports of human patients who have previously received a hematopoietic cell transplant later requiring a solid organ (kidney) transplant. In these instances, the kidney transplant from the same person who had previously supplied the bone marrow transplant is immunologically accepted without further immunosuppression. See T. Spitzer et al., 68 Transplantation 480-484 (1999).
Work in canine models and more recently in human clinical trials has shown that milder non-myeloablative conditioning regimens can be used to better prepare hosts for allogenic HCT. Here, only moderate doses of total body irradiation and a short course of immunosuppression are used to prepare the hosts prior to receiving allogeneic HCTs.
Even though the preferred embodiments have been described above, it will be appreciated by those skilled in the art that other modifications can be made within the scope of the invention. For example, while two specific stromal type cells have been selected for use, many others are also suitable. For example, one publicly available stromal cell line is the M2-lOB4 cell line having ATCC designation number CRL-1972.
Further, while the above description focuses on the creation of precursors for red blood cells and bone marrow, various other blood-related cells of interest can be obtained in quantity using the above techniques. See also U.S. patent 5,914,268. Thus, the claims should be looked to in order to judge the full scope of the invention.
Industrial Applicability The invention provides blood-related cells useful for transplantation, research and other purposes.
CROSS REFERENCES TO RELATED APPLICATIONS
Not applicable.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
__ __ BACKGROUND OF THE INVENTION
The present invention relates to the use of human embryonic stem cells to create blood-related cells, and the use of those blood-related cells for various purposes.
Techniques for isolating stable cultures of human embryonic stem cells have recently been described by our laboratory. See U.S. patent 5,843,780 and J. Thomson et al., 282 Science 1145-1147 (1998).
We have deposited two of our human embryonic stem cell lines with the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20170-2209 U.S.A. on July 7, 1999 and July 15, 1999 respectively.
Taxonomic descriptions of these deposits are human embryonic stem cell lines H1 and H9 respectively. It has been proposed in these publications that such cell lines may be used for, among other things, providing a source of specified cell lines of various types for research, transplantation and other purposes.
Under the storage and culturing conditions described in these publications the cell lines are maintained long term without differentiation into specific cell types.
When the cell lines are subsequently injected into immunodeficient mice, they form teratomas demonstrating differentiation into multiple tissue types.
When ES cells are used to produce desired cells, it is often preferable to optimize differentiation towards specific cell types. In the case of hematopoietic cells it is desirable that this result in hematopoietic cells that can be isolated and used to form multiple hematopoietic lineages. These cells may include, but not be limited to, hematopoietic stem cells.
Hematopoietic stem cell populations have been isolated directly from bone marrow. See C. Baum et al.
89 PNAS USA 2804-2808 (1992). However, this relies on a supply of bone marrow to obtain the cells.
There have also been some attempts to direct murine embryonic cell populations towards hematopoietic cells.
See e'a. U.S. patent 5,914,268; G. Keller, 7 Current Opinion In Cell Biology, 862-869 (1995); and T. Nakano et al. 265 Science 1098-1101 (1994). See also M. Weiss, 11 Aplastic Anemia And Stem Cell Biology, 1185-1195 (1997);
and S. Morrison et al., 11 Annu. Rev. Cell Dev. Biol., 35-71 (1995).
However, applying these teachings to primates has proven difficult. For example, in F. Li et al., 92 Blood 368a (1998) there was a discussion of techniques for differentiation of rhesus embryonic stem cell lines using a stromal cell line and exogenous cytokines. However, that group has more recently reported that their techniques had inadequate formation of colonies.
The treatment of various diseases by tissue transplantation has become routine. However, there can be waiting lists to obtain natural donated organs, cells, or tissue. Even when the natural donor material becomes available there is often a problem with rejection.
Traditional approaches for suppressing an immune response of recipients have drawbacks. For example, immunosuppressive drugs are costly and often have side effects.
In WO 98/07841 there was discussed techniques of deriving embryonic stem cells that are MHC compatible with a selected donor (e. g. transplanting a donor nucleus into an enucleated oocyte, followed by derivation of the stem cells therefrom). The application suggested that the resulting cells could be used to obtain MHC
compatible hematopoietic stem cells for use in medical treatments requiring bone marrow transplantation.
However, some diseases such as type 1 diabetes mellitus or multiple sclerosis involve an autoimmune response. For example, merely transplanting pancreatic islets (which are MHC compatible to the diseased individual) to replace destroyed pancreatic islets will not provide sufficient long term reduction in type 1 diabetes mellitus, as the immune system of the host will still attack the transplanted islets.
It can therefore be seen that a need exists for techniques for causing human embryonic stem cell cultures to differentiate to desired hematopoietic colonies.
Further, it is desired to develop improved uses for hematopoietic cells.
BRIEF SUMMARY OF THE INVENTION
In one aspect the present invention provides a method for obtaining human hematopoietic cells. One exposes a human embryonic stem cell culture to mammalian hematopoietic stromal cells so as to thereby create human hematopoietic cells. At least some of the human hematopoietic cells that are so created are CD34+ and/or are capable of forming hematopoietic cell colony forming units in methylcellulose culture.
CD34 is a standard marker for hematopoietic stem cells, as described in C. Baum et al. 89 PNAS USA 2809-2808 (1992) and S. Morrison et al., 11 Annu. Rev. Cell Dev. Biol., 35-71 (1995). The property of capability of forming a colony forming unit is indicative that the cells have the desired characteristics to form more differentiated hematopoietic lineages.
The stromal cells are preferably derived from bone marrow cells or embryonic yolk sac cells. Murine stromal cells may be used for this purpose. However, primate WO 01/34776 CA 02390281 2002-05-03 pCT/US00/23469 stromal and other mammalian stromal cells should be suitable as well.
In another aspect the invention provides a human hematopoietic cell which was derived from a human embryonic stem cell culture in vitro, and is capable of forming hematopoietic cell colony forming units in methylcellulose culture. As used in this patent, the term "derived" is intended to mean obtained directly or indirectly (e.g. through one or more intermediates or passages).
In yet another aspect the invention provides a method of transplanting human cellular material into a human recipient host. One obtains human hematopoietic cells which have been derived in vitro from an embryonic stem cell culture. One then obtains a selected human cellular material other than hematopoietic cells, the selected non-hematopoietic material having major histocompatibility complex compatibility to the hematopoietic cells. One then transplants both the hematopoietic cells and selected human non-hematopoietic cellular material into the human host.
For example, one can obtain human hematopoietic cells which have been derived in vitro from an embryonic stem cell culture (e. g. using the techniques described below). One also obtains human pancreatic islets which have MHC compatibility to the hematopoietic cells. Both the hematopoietic cells and pancreatic islets are then transplanted into the human (preferably after the recipient's own bone marrow has been inactivated).
The pancreatic islets can be obtained directly from a donor whose cells were used to create the embryonic stem cell culture. Alternatively, a single embryonic stem cell culture can be differentiated along two different paths. In one process the above technique can be used to create hematopoietic stem cells. These cells should develop into multiple hematopoietic lineages when WO 01/34776 CA 02390281 2002-05-03 pCT/US00/23469 transplanted into appropriate hosts. These lineages should include lymphocytes which would be tolerant of other cells derived from the same parental embryonic stem cells. In another process the stem cells would be directed towards pancreatic islets.
In another example one could supply oligodendrocytes to a human who has a multiple sclerosis condition. One obtains human hematopoietic cells which have been derived in vitro from an embryonic stem cell culture (e. g. using a technique described below). One also obtains human oligodendrocytes which have MHC compatibility to the bone marrow cells and transplants both the bone marrow cells and oligodendrocytes into the human.
The same human whose genetic material was used to create the embryonic stem cell can be a donor for the oligodendrocytes. Alternatively, the same embryonic stem cell culture can be differentiated along two separate paths to provide the two transplantable materials.
With respect to either disease (and potentially other autoimmune diseases) the immune and autoimmune rejection problems should be reduced by this technique.
In this regard, the recipient's original bone marrow can be totally or partially inactivated by radiation or chemical means before the transplantation. Thereafter, it is replaced at least in part by the transplanted hematopoietic cells. The elimination/reduction of the original bone marrow reduces the body's ability to create an autoimmune response. The matching of the MHC of the replacement bone marrow and the second transplantable material insures that the second material won't be rejected by the transplanted bone marrow.
Moreover, co-transplantation of hematopoietic cells and other tissue can be done to promote acceptance of the second tissue (e. g. heart muscle plus hematopoietic cells for treating heart disease; hepatocytes plus hematopoietic cells for treating liver disease). By creating hematopoietic chimeras improved acceptance of tissues with similarly matched MHC type can be obtained.
The present invention should be suitable to obtain a wide variety of hematopoietic cells of interest, such as erythroid cells, granulocyte cells, macrophages, lymphocyte precursors, monocytes, B cells, T cells, and the like. In this regard, colonies of differentiated ES
cells develop into hematopoietic colonies when harvested, separated into single cells, and plated into appropriate cultures. These colonies demonstrate the development of colony-forming cells which proliferate into colony-forming units (including colony forming unit-erythroid (CFU-E), blast forming unit-eythroid (BFU-E), colony forming unit-macrophage (CFU-M), colony forming unit-granulocyte/macrophage (CFU-GM) and colony forming unit-high proliferative potential (CFU-HPP)). The identification of colony forming cells indicates the differentiation of embryonic stem cells into hematopoietic cells capable of expanding into defined hematopoietic lineages under defined conditions.
The objects of the present invention therefore include providing:
(a) methods of the above kind for obtaining hematopoietic cells;
(b) cells derived using those methods; and (c) methods for using those derived cells for transplantation, transfusion and other purposes.
These and still other objects and advantages of the present invention will be apparent from the description of the preferred embodiments that follows. However, the claims should be looked to in order to judge the full scope of the invention.
DETAILED DESCRIPTION
Embryonic Stem Cell Culture The previously described human ES cell line Hl was used for the majority of experiments, albeit some of the WO 01/34776 CA 02390281 2002-05-03 pCT/US00/23469 following studies were done with the previously described ES cell lines H9 (or H9.2) with similar results. These cells were removed from frozen (liquid nitrogen) stocks of cells derived from the original isolated and propagated cell line. The Hl ES cells were grown in 6 well culture dishes (Nunclon, Fisher).
The dish was first coated with O.lo gelatin solution (Sigma) for one or more days in a 37°C/5o CO~ incubator.
After the one or more days, the gelatin solution was removed and the wells of the plate were next coated with irradiated mouse embryonic fibroblast (MEF) cells. MEF
cells were derived from day 12-13 mouse embryos in medium consisting of DMEM (GibcoBRL) supplemented with loo fetal bovine serum (Hyclone or Harlan), 2 mM 1-glutamine (GibcoBRL), and 100 units/ml. Penicillin, 100 mg/ml streptomycin (Sigma).
The MEF cells were irradiated with 5500 cGy from a cesium source prior to plating in the wells. The MEFs were added at a density of 5 x lO4cells/ml, 2.5 ml/well.
The plate coated with MEFs was then placed in 37°C/5o CO2 incubator for one or more days until addition of ES
cells.
ES cells were passed onto new MEFs at approximately 5-8 day intervals. The time depends on cell density and morphologic appearance of differentiation. For passage, the medium in a well of ES cells was removed and 1-2 ml of medium containing 1 mg/ml collagenase IV in DMEM
(GibcoBRL) was added. The plate was then placed at 37°C/5o CO2 for 5-20 minutes until the colonies of ES
cells began to round up.
The well was then scraped with a 5 ml pipette to detach the ES cells from the plate. The contents of the harvested well were placed in a 15 ml conical tube (Fisher) and spun in a centrifuge at 1000 rpm for 5 minutes. The medium was removed and 10 ml of fresh medium was added. This ES cell medium consists of F12/DMEM
_7_ (GibcoBRL)) supplemented with 20o serum replacement medium (GibcoBRL), 8 ng/ml of bFGF (GibcoBRL), 1o non-essential amino acid solution (GibcoBRL), 1 mM 1-glutamine (GibcoBRL), and 0.1M (3-mercaptoethanol.
The cells were again spun (5 min/1000 rpm), medium removed and resuspended at a concentration of 2.5 ml of medium for each (typically 15 ml medium for plating into 6 new wells, this would be a 1:6 passage). The cells were then pipetted into the wells of a plate that had been previously coated with MEFs as described above. The cells were evenly distributed into each well and the plate was placed in an incubator at 37°C/5o CO2.
At times if there were colonies of ES cells showing morphologic appearance of differentiation prior to cell passage, these colonies were removed by gentle scraping with a pulled glass pipette. This was done with observation through a dissecting microscope. After removal of the differentiated cells, the remaining colonies were passaged as above.
After passage, each well of ES cells was "fed" with fresh medium at 24-48 hour intervals. Here, the medium of each well was removed and 2.5 ml of fresh ES medium was added. All feeding and passage of ES cells were done in a sterile environment.
Differentiation Of ES Cells To promote hematopoietic differentiation of the human ES cells, the ES cells were harvested as above. The cells were then plated in 6 well plates coated with a mammalian stromal cell. In one experiment we used C166 cells that were previously irradiated with 2500 cGy. The C166 cells were originally obtained from the yolk sac of mice at embryonic day 12 and were graciously provided by Dr. Robert Auerbach (UW-Madison).
In another experiment, S17 cells were used. They were originally obtained from mouse bone marrow, and were -g-graciously provided by Dr. Kenneth Dorshkind (then at UC-Riverside, now at UCLA).
The C166 or S17 cells were plated at a density of 1 x 10'' cells/ml, 2.5 ml/well. The ES cells plated onto either S17 of C166 cells were then allowed to grow in a medium consisting of DMEM (GibcoBRL) supplemented with 20o fetal bovine serum (Hyclone), to nonessential amino acid solution, O.1M (3-mercaptoethanol, and 1 mM 1-glutamine. This medium was replaced in each well at 24-72 hour intervals with fresh medium. In selecting an appropriate medium, one merely needs to provide conventional conditions for cell growth, albeit supplemented with the specified stromal cells.
After 3-7 days from plating onto S17 or C166 cells, the ES cells began to visually appear differentiated in that they did not have the same uniform appearance as the undifferentiated ES cells maintained on MEF feeder cells.
The colonies of ES cells began to form multiple different cell types. Some of these colonies had regions that appeared to consist of cells with a cobblestone morphology indicative of colonies of early hematopoietic progenitor cells.
Confirming Blood-Related Cells One method to determine the presence of appropriate hematopoietic cells is to assay for hematopoietic colony forming cells (CFCs) in semisolid methylcellulose-containing medium. Here, the ES cells were allowed to differentiate on either C166 or S17 cells for 2-3 weeks, maintained as described above. After this time the medium was removed. 2.5 ml of calcium and magnesium free phosphate buffered saline (PBS) was added for 2-5 minutes, removed, and 1.5 ml. of trypsin (0.125x)-EDTA
(1mM) medium was added.
The cells were then placed at 37°C/5o C02 for 10 minutes. After this time, the colonies began to disassociate. The cells were further disassociated by _g_ pipetting and scraping the wells. The cells were placed in a 15 ml. conical, spun 5 min/1000 rpm, medium removed and 10 ml fresh medium (DMEM + 10 o FBS + 1-glutamine+
pen/strep) was added, and spun again. The cells were then suspended in 5 ml medium and passaged through a 100 mM
nytex filter to remove clumps of cells.
The filter was washed with an additional 5 ml medium. The disassociated/filtered cells were then counted on a hemacytometer and 1 x 10~ (usually, but not always this many cells) cells were placed in a new 15 ml conical. These cells were then spun, medium removed and 5 ml medium consisting of IMDM (GibcoBRL) supplemented with 2o fetal bovine serum (Hyclone) was added. Cells were spun, medium removed and 250 ul medium (IMDM + 2o FBS) was added.
In accordance with the specified test conditions, these cells were then added to 2.5 ml of Methocult GF+
H4435 medium (StemCell Technologies). This medium consists of l.Oo methylcellulose, supplemented with 300 FBS, 20 ng/ml IL-3, 20 ng/ml IL-6, 50 ng/ml stem cell factor, 3 units/ml erythropoietin, 20 ng/ml GM-CSF, 20 ng/ml G-CSF, 2 mM 1-glutamine, O.lmM b-mercaptoethanol, 1% bovine serum albumin. The cells in methylcellulose were then vortexed vigorously and then 1.1 ml of the mixture was plated onto a P35 plastic dish (Stem Cell Technologies), spread evenly on the dish and placed at 37°C/5% CO,.
Duplicate plates of each sample were typically plated with 4 x 10' cells/plate. After 14-21 days, the plates were analyzed under a microscope for the presence of hematopoietic colonies. The colonies were identified by comparison to a colony atlas (StemCell Technologies) or the book: Culture of Hematopoietic Cells, RI Freshney, IB Pragnell, MG Freshney, eds., Wiley-Liss, Inc. 1994.
Colonies were identified as one of the following: colony forming unit-erythroid (CFU-E), blast forming unit-WO 01/34776 CA 02390281 2002-05-03 pCT/US00/23469 eythroid (BFU-E), colony forming unit-macrophage (CFU-M), colony forming unit-granulocyte/macrophage (CFU-GM) or colony forming unit-high proliferative potential (CFU-HPP) .
The presence of the desired hematopoietic cells can also be confirmed by flow cytometry. One can look for specified cell surface antigens by flow cytometry. Here, ES cells differentiated on S17 cells or C166 cells as described above for 14-21 days, were harvested with trypsin/EDTA as described above and passed through a 100 mM nytex filter. The filtered cells were counted on a hemacytometer, then aliquotted into 15 X 75 plastic tubes (Fisher) at approximately 1 x 105 cells/tube. The cells were then spun, medium removed and 2-3 ml of FACS medium was added. (FRCS medium is PBS with O.So BSA (Sigma), O.lo sodium azide (Sigma)).
The cells were again spun and medium removed. Next an antibody directly linked to a fluorescent marker (FITC
or PE) was added to the wells at a concentration as recommended by the supplier. Cells have been analyzed with the following antibodies: CD34-FITC (Immunotech), CD45-PE (Pharmingen). IgG1-FITC and IgGl-PE were used as isotype controls for non-specific staining of the cells.
Cells were incubated with the appropriate antibody for approximately 30 min on ice, washed 1-2 times with 2-3 ml FAGS medium and resuspended in approximately 0.5 ml FRCS
medium.
The antibody labeled cells were then analyzed using a FACScan (Becton Dickinson) as per manufacturers recommendations. The presence of dead cells was determined by addition of propidium iodide (1 mg/ml solution, 5 ul added per tube) or 7-AAD (Calbiochem) (0.2 mg/ml ,5 ul/tube). The software for analysis was eithe r PC Lysis or Cellquest.
The following experimental techniques were used to analyze antigen expression by immunohistochemistry (IHC).
WO 01/34776 CA 02390281 2002-05-03 pCT~S00/23469 Here, differentiated ES cells that have been co-cultured with either C166 or S17 as above, were harvested with trypsin/EDTA as above. The cells were resuspended in medium containing DMEM supplemented with loo FBS at a concentration of approximately 1 x 109 - 1 x 10'.
"Cytospin" preparations of these cells were then made by spinning 1 x 10=~ - 1x 104 cells onto a glass slide (Superfrost/plus, Fisher) with a Cytospin II centrifuge (Shanndon).
These slides were then fixed with cold acetone and stored frozen at -20°C. For IHC staining the slides were thawed at room temperature and the cell pellet was outlined with a wax pen (DAKO). The cells were then stained as follows using a Vectastain ABC kit (Vector Laboratories, Burlingame, CA), all incubations were at room temperature. 100-200 ul PBS was added onto the cells for 5 minutes then removed. Vectastain blocking antibody solution (horse serum) was then added onto the cells for 15 minutes. The cells were then blotted dry and 100-200 ul of primary antibody solution was added. The primary antibodies were: IgGl (1 ug/sample, Sigma), anti-CD34 (0.5 ug/sample, Immunotech), anti-CD45 (1 ug/sample, DAKO), anti-class I (1 ug/sample, gift from Dr. Paul Leibson, Mayo Clinic), anti-CD14 (1 ug/sample, Pharmingen), anti-CD31 (1 ug/sample, Pharmingen).
Primary antibody was added for 30 minutes followed by PBS for 10 minutes. Next, biotinylated anti-IgG
antibody was added (Vectastain kit, solution B) for 30 minutes followed by PBS for 10 minutes. Next Vectastain ABC solution was added for 30 minutes at room temperature followed by PBS for 10 minutes. Next DAB solution (Vectastain) was added for 5 minutes followed by washing under running tap water for 10 minutes. In some experiments, the slides were then counterstained with Gill's hematoxylline solution (Vector labs) for 3 minutes followed by washing with running tap water for 10 minutes. The slides were then air dried. Cells staining positive appear brown.
CD34+ was demonstrated within a mixed population of cells (about lo) after 2-3 weeks. Even more importantly, differentiated ES cells were shown to develop into hematopoietic colonies when harvested, separated into cells and plated into methylcellulose (semi-solid) cultures.
Transplantation Currently hematopoietic cell transplantation is conducted clinically primarily for patients who have received high dose chemotherapy for treatment of malignancies. These patients typically receive a heterogeneous mixture of hematopoietic cells either from an autologous or allogeneic source. Human ES-derived hematopoietic stem cells will at minimum provide a more homogeneous cell population for hematopoietic cell transplantation.
Further, as discussed above, the MHC characteristics of the transplantation can now be controlled, thereby enabling treatment of autoimmune diseases. For example, both hematopoietic stem cells (HSCs) and a second lineage (e. g. pancreatic islets for diabetes or oligodendrocytes for multiple sclerosis) could be derived from the same parental ES cell line. With both lineages available, a hematopoietic chimera could be first created by performing a fully allogeneic hematopoietic cell transplant (HCT). The established state of chimerism would allow the recipient's immune system to "see" the subsequent transplant of the second cell type (e. g.
pancreatic islets cell or oligodendrocyte) as "self" and should not be rejected.
Note for example that oligodendrocytes have been obtained from mouse ES cells (O. Brustle et al., 285 Science 754-6 (1999)), as have cardiac muscle cells (M.
Klug et al., 98 J. Clin. Invest. 216-224 (1996)).
This method of creating hematopoietic chimeras will also promote acceptance of tissues transplanted for reasons other than autoimmunity. In this regard, mice receiving allogeneic hematopoietic stem cells do not reject other tissues with the same genetic background as the hematopoietic cells, but will still reject third-party grafts. See K. Gandy et al., 65 Transplantation 295-304 (1998).
In addition to animal studies, there are now clinical case reports of human patients who have previously received a hematopoietic cell transplant later requiring a solid organ (kidney) transplant. In these instances, the kidney transplant from the same person who had previously supplied the bone marrow transplant is immunologically accepted without further immunosuppression. See T. Spitzer et al., 68 Transplantation 480-484 (1999).
Work in canine models and more recently in human clinical trials has shown that milder non-myeloablative conditioning regimens can be used to better prepare hosts for allogenic HCT. Here, only moderate doses of total body irradiation and a short course of immunosuppression are used to prepare the hosts prior to receiving allogeneic HCTs.
Even though the preferred embodiments have been described above, it will be appreciated by those skilled in the art that other modifications can be made within the scope of the invention. For example, while two specific stromal type cells have been selected for use, many others are also suitable. For example, one publicly available stromal cell line is the M2-lOB4 cell line having ATCC designation number CRL-1972.
Further, while the above description focuses on the creation of precursors for red blood cells and bone marrow, various other blood-related cells of interest can be obtained in quantity using the above techniques. See also U.S. patent 5,914,268. Thus, the claims should be looked to in order to judge the full scope of the invention.
Industrial Applicability The invention provides blood-related cells useful for transplantation, research and other purposes.
Claims (6)
PROPERTY OF PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A method for obtaining human hematopoietic cells, comprising culturing human embryonic stem cells on a layer of mammalian hematopoietic stromal cells in the presence of medium, such that the human embryonic stem cells differentiate into human hematopoietic cells.
2. The method of claim 1, wherein the human hematopoietic cells that are obtained are CD34+.
3. The method of claim 1, wherein the human hematopoietic cells that are obtained form hematopoietic cell colony forming units in methylcellulose culture.
4. The method of claim 1, wherein the stromal cells are selected from the group consisting of bone marrow cells and embryonic yolk sac cells.
5. A method for obtaining human hematopoietic cells, comprising culturing human embryonic stem cells in vitro on a layer of mammalian hematopoietic stromal cells in the presence of medium, such that the human embryonic stem cells differentiate into human hematopoietic cells, wherein the human hematopoietic cells that are obtained form erythroid blast forming units in methylcellulose culture.
6. The method of claim 5, wherein the cell culture has hematopoietic cells that are CD34+.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/435,578 | 1999-11-08 | ||
US09/435,578 US6280718B1 (en) | 1999-11-08 | 1999-11-08 | Hematopoietic differentiation of human pluripotent embryonic stem cells |
PCT/US2000/023469 WO2001034776A1 (en) | 1999-11-08 | 2000-08-25 | Hematopoietic differentiation of human embryonic stem cells |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2390281A1 CA2390281A1 (en) | 2001-05-17 |
CA2390281C true CA2390281C (en) | 2005-10-25 |
Family
ID=23728955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002390281A Expired - Lifetime CA2390281C (en) | 1999-11-08 | 2000-08-25 | Hematopoietic differentiation of human embryonic stem cells |
Country Status (13)
Country | Link |
---|---|
US (3) | US6280718B1 (en) |
EP (1) | EP1228194A1 (en) |
JP (3) | JP2003513664A (en) |
KR (2) | KR20030022766A (en) |
CN (1) | CN1228443C (en) |
AU (1) | AU784928B2 (en) |
BR (1) | BR0015374A (en) |
CA (1) | CA2390281C (en) |
IL (2) | IL149387A0 (en) |
IS (1) | IS6373A (en) |
NO (1) | NO20022180L (en) |
SE (1) | SE526490C2 (en) |
WO (1) | WO2001034776A1 (en) |
Families Citing this family (176)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7410798B2 (en) * | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
WO2000027995A1 (en) * | 1998-11-09 | 2000-05-18 | Monash University | Embryonic stem cells |
US8252280B1 (en) | 1999-08-05 | 2012-08-28 | Regents Of The University Of Minnesota | MAPC generation of muscle |
US7015037B1 (en) * | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
US10638734B2 (en) | 2004-01-05 | 2020-05-05 | Abt Holding Company | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
US20030129745A1 (en) | 1999-10-28 | 2003-07-10 | Robl James M. | Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
US6280718B1 (en) * | 1999-11-08 | 2001-08-28 | Wisconsin Alumni Reasearch Foundation | Hematopoietic differentiation of human pluripotent embryonic stem cells |
US6602711B1 (en) * | 2000-02-21 | 2003-08-05 | Wisconsin Alumni Research Foundation | Method of making embryoid bodies from primate embryonic stem cells |
US6534052B1 (en) | 2000-09-05 | 2003-03-18 | Yong-Fu Xiao | Cardiac function comprising implantation of embryonic stem cell in which differentiation has been initiated |
US6607720B1 (en) | 2000-09-05 | 2003-08-19 | Yong-Fu Xiao | Genetically altered mammalian embryonic stem cells, their living progeny, and their therapeutic application for improving cardiac function after myocardial infarction |
IL156303A0 (en) | 2000-12-06 | 2004-01-04 | Robert J Hariri | Method of collecting placental stem cells |
US7311905B2 (en) | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
EP1366148A2 (en) * | 2001-01-24 | 2003-12-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES | Differentiation of stem cells to pancreatic endocrine cells |
EP1367899A4 (en) * | 2001-02-14 | 2004-07-28 | Leo T Furcht | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
EP1362095B1 (en) | 2001-02-14 | 2015-05-27 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
US20030211605A1 (en) * | 2001-05-01 | 2003-11-13 | Lee Sang-Hun | Derivation of midbrain dopaminergic neurons from embryonic stem cells |
AU2002317039B2 (en) | 2001-07-24 | 2007-10-04 | Es Cell International Pte Ltd | Methods of inducing differentiation of stem cells |
MXPA04001725A (en) * | 2001-08-24 | 2005-04-11 | Advanced Cell Tech Inc | Screening assays for identifying differentiation-inducing agents and production of differentiated cells for cell therapy. |
DE10144326B4 (en) * | 2001-09-10 | 2005-09-22 | Siemens Ag | Method and system for monitoring a tire air pressure |
US6759244B2 (en) * | 2001-11-08 | 2004-07-06 | Art Institute Of New York And New Jersey, Inc. | Composite blastocysts (CBs) from aggregates of dissociated cells of non-viable pre-embryos |
PL373957A1 (en) * | 2001-11-09 | 2005-09-19 | Artecel Sciences, Inc. | Methods and compositions for the use of stromal cells to support embryonic and adult stem cells |
US20040224403A1 (en) * | 2001-12-07 | 2004-11-11 | Robarts Research Institute | Reconstituting hematopoietic cell function using human embryonic stem cells |
JP5364224B2 (en) * | 2001-12-07 | 2013-12-11 | ジェロン・コーポレーション | Hematopoietic cells derived from human embryonic stem cells |
AU2012258384B2 (en) * | 2001-12-07 | 2016-04-21 | Asterias Biotherapeutics, Inc. | Hematopoietic cells from human embryonic stem cells |
US7799324B2 (en) * | 2001-12-07 | 2010-09-21 | Geron Corporation | Using undifferentiated embryonic stem cells to control the immune system |
AU2016206280B2 (en) * | 2001-12-07 | 2018-05-17 | Asterias Biotherapeutics, Inc. | Hematopoietic cells from human embryonic stem cells |
AU2003235652A1 (en) * | 2002-01-15 | 2003-07-30 | Advanced Cell Technology, Inc. | Cloning b and t lymphocytes |
US20050090004A1 (en) * | 2003-01-16 | 2005-04-28 | Sayre Chauncey B. | Stem cell maturation for all tissue lines |
US20030134422A1 (en) * | 2002-01-16 | 2003-07-17 | Sayre Chauncey Bigelow | Stem cell maturation for all tissue lines |
US20050170506A1 (en) * | 2002-01-16 | 2005-08-04 | Primegen Biotech Llc | Therapeutic reprogramming, hybrid stem cells and maturation |
EP1490478A4 (en) * | 2002-03-18 | 2006-03-22 | Nat Jewish Med & Res Center | Method for production of neutrophils and uses therefor |
US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
GB0210741D0 (en) * | 2002-05-10 | 2002-06-19 | Medical Res Council | Methods of therapy |
US20040091936A1 (en) * | 2002-05-24 | 2004-05-13 | Michael West | Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank |
EP1513928B1 (en) | 2002-05-24 | 2019-08-21 | Advanced Cell Technology, Inc. | A bank of stem cells for producing cells for transplantation having hla antigens matching those of transplant recipients, and methods for making and using such a stem cell bank |
CN1668733A (en) * | 2002-05-30 | 2005-09-14 | 细胞基因公司 | Methods of using JNK or MKK inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes |
US20060121607A1 (en) * | 2002-08-08 | 2006-06-08 | Thomas Schulz | Compositions and methods for neural differentiation of embryonic stem cells |
WO2004035748A2 (en) * | 2002-10-16 | 2004-04-29 | Advanced Cell Technology, Inc. | Methods using gene trapped stem cells for marking pathways of stem cell differentiation and making and isolating differentiated cells |
GB0224415D0 (en) * | 2002-10-21 | 2002-11-27 | Medical Res Council | Compositions |
WO2004047770A2 (en) | 2002-11-26 | 2004-06-10 | Anthrogenesis Corporation | Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
EP1567639A4 (en) * | 2002-12-05 | 2005-12-21 | Technion Res & Dev Foundation | Cultured human pancreatic islets, and uses thereof |
US20040110286A1 (en) * | 2002-12-06 | 2004-06-10 | The John P. Robarts Research Institute | Method for making hematopoietic cells |
KR20050105467A (en) * | 2003-02-13 | 2005-11-04 | 안트로제네시스 코포레이션 | Use of umbilical cord blood to treat individuals having a disease, disorder or condition |
US20060177929A1 (en) * | 2003-03-24 | 2006-08-10 | Klug Christopher A | Regulation of self-renewal in stem cells |
AU2004227204B2 (en) | 2003-04-08 | 2010-06-03 | Yeda Research And Development Co. Ltd | Stem cells having increased sensitivity to SDF-1 and methods of generating and using same |
FR2853551B1 (en) | 2003-04-09 | 2006-08-04 | Lab Francais Du Fractionnement | STABILIZING FORMULATION FOR IMMUNOGLOBULIN G COMPOSITIONS IN LIQUID FORM AND LYOPHILIZED FORM |
AU2004242091C1 (en) * | 2003-05-07 | 2009-12-24 | La Jolla Institute For Molecular Medicine | Administration of hyaluronic acid to enhance the function of transplanted stem cells |
NZ547105A (en) * | 2003-10-16 | 2009-02-28 | Univ Edinburgh | Control of ES cell self-renewal and lineage specification, and medium therefor |
IL158868A0 (en) | 2003-11-13 | 2004-05-12 | Yeda Res & Dev | Methods of generating and using stem cells enriched with immature primitive progenitor |
US20070141703A1 (en) * | 2003-11-19 | 2007-06-21 | Stanley Edouard G | Methods for producing blood products from pluripotent cells in cell culture |
JP4676442B2 (en) * | 2003-12-02 | 2011-04-27 | セラヴィー バイオサイエンシズ エルエルシー | Compositions and methods for growing neural progenitor cells |
US20070269412A1 (en) * | 2003-12-02 | 2007-11-22 | Celavie Biosciences, Llc | Pluripotent cells |
WO2005080551A2 (en) * | 2004-02-12 | 2005-09-01 | University Of Newcastle Upon Tyne | Stem cells |
US20050232905A1 (en) * | 2004-03-26 | 2005-10-20 | Yeh Edward T | Use of peripheral blood cells for cardiac regeneration |
WO2005097979A2 (en) * | 2004-03-31 | 2005-10-20 | Newlink Genetics Corporation | Methods and compositions for obtaining hematopoietic stem cells derived from embryonic stem cells and uses thereof |
US7622108B2 (en) * | 2004-04-23 | 2009-11-24 | Bioe, Inc. | Multi-lineage progenitor cells |
CN101080486B (en) * | 2004-04-23 | 2012-05-16 | 佰欧益股份有限公司 | Multi-lineage progenitor cells |
WO2005113749A2 (en) | 2004-05-14 | 2005-12-01 | Becton, Dickinson And Company | Stem cell populations and methods of use |
EP1809739B1 (en) | 2004-07-13 | 2014-10-15 | Asterias Biotherapeutics, Inc. | Medium for growing human embryonic stem cells |
CA2504451A1 (en) * | 2004-08-10 | 2006-02-10 | Geron Corporation | Dendritic cell vaccines for treating cancer made from embryonic stem cells |
EP1799810A2 (en) * | 2004-10-12 | 2007-06-27 | Technion Research & Development Foundation Ltd. | Isolated primate embryonic cells and methods of generating and using same |
WO2006050330A2 (en) * | 2004-11-01 | 2006-05-11 | Wisconsin Alumni Research Foundation | Platelets from stem cells |
US20070077654A1 (en) * | 2004-11-01 | 2007-04-05 | Thomson James A | Platelets from stem cells |
US20060263879A1 (en) * | 2004-12-30 | 2006-11-23 | Stemlifeline, Inc. | Methods and systems relating to embryonic stem cell lines |
US20060275899A1 (en) * | 2004-12-30 | 2006-12-07 | Stemlifeline, Inc. | Methods and compositions relating to embryonic stem cell lines |
WO2006086746A2 (en) * | 2005-02-09 | 2006-08-17 | Burnham Institute For Medical Research | Homogeneous neural precursor cells |
AU2006243800B2 (en) | 2005-05-04 | 2012-02-02 | Commonwealth Scientific And Industrial Research Organisation | Selecting, culturing and creating lineage committed hematopoietic stem cells |
US8034613B2 (en) | 2005-06-01 | 2011-10-11 | Wisconsin Alumni Research Foundation | Multipotent lymphohematopoietic progenitor cells |
AU2006252576B2 (en) * | 2005-06-01 | 2011-01-20 | Wisconsin Alumni Research Foundation | Method of forming dendritic cells from embryonic stem cells |
JP5560393B2 (en) | 2005-06-22 | 2014-07-23 | アステリアス バイオセラピューティクス インコーポレイテッド | Differentiation of primate pluripotent stem cells into cardiomyocyte lineage cells |
GB2441488C (en) * | 2005-06-22 | 2011-10-05 | Geron Corp | Suspension culture of human embryonic stem cells |
EP1904624B1 (en) * | 2005-07-20 | 2011-09-21 | Seoul National University Industry Foundation | Method for culturing and proliferating hematopoietic stem cells and progenitor cells using human endometrial cells |
EP2530145A1 (en) | 2005-10-13 | 2012-12-05 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
US8048999B2 (en) | 2005-12-13 | 2011-11-01 | Kyoto University | Nuclear reprogramming factor |
US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
EP1976978A2 (en) | 2005-12-29 | 2008-10-08 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
ES2549111T3 (en) | 2005-12-29 | 2015-10-23 | Anthrogenesis Corporation | Placental stem cell populations |
US7727763B2 (en) * | 2006-04-17 | 2010-06-01 | Bioe, Llc | Differentiation of multi-lineage progenitor cells to respiratory epithelial cells |
EP2064319B1 (en) | 2006-08-28 | 2017-02-22 | Yeda Research and Development Co. Ltd. | Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns |
US20080108044A1 (en) * | 2006-11-08 | 2008-05-08 | Deepika Rajesh | In vitro differentiation of hematopoietic cells from primate embryonic stem cells |
CA2670497A1 (en) * | 2006-11-24 | 2008-05-29 | Regents Of The University Of Minnesota | Endodermal progenitor cells |
US7883698B2 (en) * | 2007-01-17 | 2011-02-08 | Maria Michejda | Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use |
NZ597779A (en) | 2007-02-12 | 2013-07-26 | Anthrogenesis Corp | Treatment of inflammatory diseases using placental stem cells |
JP2008307007A (en) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth |
US9029147B2 (en) * | 2007-06-15 | 2015-05-12 | Massachusetts Institute Of Technology | Methods and compositions for enhanced differentiation from embryonic stem cells |
US9213999B2 (en) | 2007-06-15 | 2015-12-15 | Kyoto University | Providing iPSCs to a customer |
US20090029463A1 (en) * | 2007-07-25 | 2009-01-29 | Bioe, Inc. | Differentiation of Multi-Lineage Progenitor Cells to Chondrocytes |
EP3524253A1 (en) | 2007-09-28 | 2019-08-14 | Celularity, Inc. | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
JP5558097B2 (en) | 2007-12-10 | 2014-07-23 | 国立大学法人京都大学 | Efficient nuclear initialization method |
US9683232B2 (en) | 2007-12-10 | 2017-06-20 | Kyoto University | Efficient method for nuclear reprogramming |
AU2009241736B2 (en) * | 2008-04-30 | 2014-05-08 | Sanbio, Inc. | Neural regenerating cells with alterations in DNA methylation |
CN101855350B (en) | 2008-05-02 | 2014-12-31 | 国立大学法人京都大学 | Method of nuclear reprogramming |
CA2724839A1 (en) * | 2008-05-21 | 2009-11-26 | Bioe Llc | Differentiation of multi-lineage progenitor cells to pancreatic cells |
KR20180108887A (en) | 2008-08-20 | 2018-10-04 | 안트로제네시스 코포레이션 | Treatment of stroke using isolated placental cells |
EP3539380A3 (en) | 2008-08-20 | 2019-12-18 | Celularity, Inc. | Improved cell composition and methods of making the same |
CA2734446C (en) | 2008-08-22 | 2017-06-20 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
RU2562154C2 (en) | 2008-11-19 | 2015-09-10 | Антродженезис Корпорейшн | Amniotic adhesive cells |
US20100209399A1 (en) * | 2009-02-13 | 2010-08-19 | Celavie Biosciences, Llc | Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects |
WO2010098079A1 (en) | 2009-02-24 | 2010-09-02 | 学校法人金沢医科大学 | Method for denucleating nucleated erythrocyte, and denucleation inducer |
WO2011005326A1 (en) | 2009-07-09 | 2011-01-13 | Massachusetts Institute Of Technology | Methods and compositions for increased safety of stem cell-derived populations |
AU2010279572B2 (en) | 2009-08-03 | 2017-02-02 | Recombinetics, Inc. | Methods and compositions for targeted gene modification |
CA2777552C (en) | 2009-10-19 | 2019-05-21 | Cellular Dynamics International, Inc. | Cardiomyocyte production |
ES2646750T3 (en) | 2010-01-26 | 2017-12-15 | Anthrogenesis Corporation | Treatment of bone-related cancers using placental stem cells |
TWI578993B (en) | 2010-04-07 | 2017-04-21 | 安瑟吉納西斯公司 | Angiogenesis using placental stem cells |
TW201138792A (en) | 2010-04-08 | 2011-11-16 | Anthrogenesis Corp | Treatment of sarcoidosis using placental stem cells |
WO2011159797A2 (en) | 2010-06-15 | 2011-12-22 | Cellular Dynamics International, Inc. | A compendium of ready-built stem cell models for interrogation of biological response |
KR20130093091A (en) | 2010-07-13 | 2013-08-21 | 안트로제네시스 코포레이션 | Methods of generating natural killer cells |
CA2806858C (en) | 2010-08-04 | 2021-06-15 | Cellular Dynamics International, Inc. | Reprogramming immortalized b cells |
CA2838330C (en) | 2010-08-23 | 2021-01-26 | President And Fellows Of Harvard College | Optogenetic probes for measuring membrane potential |
US8895291B2 (en) | 2010-10-08 | 2014-11-25 | Terumo Bct, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
WO2012054896A1 (en) | 2010-10-22 | 2012-04-26 | Biotime Inc. | Methods of modifying transcriptional regulatory networks in stem cells |
EP2658557A1 (en) | 2010-12-31 | 2013-11-06 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory rna molecules |
AU2012225784B2 (en) | 2011-03-04 | 2016-03-17 | The Regents Of The University Of California | Locally released growth factors to mediate motor recovery after stroke |
EP2691512B1 (en) | 2011-03-29 | 2019-05-01 | Asterias Biotherapeutics, Inc. | Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells |
WO2012154344A1 (en) | 2011-04-06 | 2012-11-15 | Sanbio, Inc. | Methods and compositions for modulating peripheral immune function |
TWI602570B (en) | 2011-06-01 | 2017-10-21 | 安瑟吉納西斯公司 | Treatment of pain using placental stem cells |
US10865383B2 (en) | 2011-07-12 | 2020-12-15 | Lineage Cell Therapeutics, Inc. | Methods and formulations for orthopedic cell therapy |
AU2012298997B2 (en) | 2011-08-23 | 2018-10-04 | Wisconsin Alumni Research Foundation | Angiohematopoietic progenitor cells |
WO2013055476A1 (en) | 2011-09-09 | 2013-04-18 | Anthrogenesis Corporation | Treatment of amyotrophic lateral sclerosis using placental stem cells |
EP2594295A1 (en) | 2011-11-16 | 2013-05-22 | Servicio Andaluz De Salud | Nerve implants based on a compacted biomaterial containing cells |
US9447378B2 (en) | 2012-04-27 | 2016-09-20 | Massachusetts Institute Of Technology | Method for differentiating human embryonic stem cells into β-cells for the treatment of type I diabetes |
JP5432322B2 (en) | 2012-05-08 | 2014-03-05 | 株式会社大塚製薬工場 | Mammalian cell suspension for prevention of pulmonary embolism containing trehalose |
US20140178988A1 (en) | 2012-10-08 | 2014-06-26 | Biotime, Inc. | Differentiated Progeny of Clonal Progenitor Cell Lines |
EP3622960A1 (en) | 2013-02-05 | 2020-03-18 | Celularity, Inc. | Natural killer cells from placenta |
WO2014171486A1 (en) | 2013-04-17 | 2014-10-23 | 日産化学工業株式会社 | Medium composition and method for producing red blood cells using same |
EP3003290B1 (en) | 2013-06-05 | 2021-03-10 | AgeX Therapeutics, Inc. | Compositions for use in the treatment of wounds in mammalian species |
WO2014201431A1 (en) | 2013-06-14 | 2014-12-18 | Massachusetts Institute Of Technology | Articles and methods for stem cell differentiation |
NZ714410A (en) | 2013-06-28 | 2020-02-28 | Otsuka Pharma Factory Inc | Trehalose and dextran-containing solution for transplanting mammalian cells |
CN105992816B (en) | 2013-11-16 | 2018-04-17 | 泰尔茂比司特公司 | Cell amplification in bioreactor |
CN103740642A (en) * | 2014-01-28 | 2014-04-23 | 娄彩玲 | Method for preparing human erythrocytes |
US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
JP6783143B2 (en) | 2014-03-25 | 2020-11-11 | テルモ ビーシーティー、インコーポレーテッド | Passive replenishment of medium |
US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
WO2016049421A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled feed |
CN107002040B (en) | 2014-10-24 | 2021-08-10 | 大日本住友制药株式会社 | Method for preparing retinal tissue |
US10286009B2 (en) * | 2015-05-16 | 2019-05-14 | Asterias Biotherapeutics, Inc. | Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
EP3354721B1 (en) | 2015-09-08 | 2022-06-08 | Sumitomo Pharma Co., Ltd. | Method for producing retinal pigment epithelial cells |
CA3007733A1 (en) | 2015-12-07 | 2017-06-15 | Biotime, Inc. | Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cells |
CN109069870B (en) | 2016-02-24 | 2022-04-29 | 洛克菲勒大学 | Embryonic cell-based therapeutic candidate screening systems, models for huntington's disease and uses thereof |
US11920155B2 (en) | 2016-03-30 | 2024-03-05 | Asterias Biotherapeutics, Inc. | Oligodendrocyte progenitor cell compositions |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
WO2018084228A1 (en) | 2016-11-04 | 2018-05-11 | 国立大学法人東京大学 | Solution for cryopreservation of animal cells or animal tissues, cryopreserved product, and cryopreservation method |
JP7184283B2 (en) | 2016-11-25 | 2022-12-06 | 国立研究開発法人理化学研究所 | CELL POPULATION FOR TRANSPLANTATION AND METHOD FOR PRODUCING THE SAME |
US11889829B2 (en) | 2016-12-14 | 2024-02-06 | Otsuka Pharmaceutical Factory, Inc. | Mammalian cell cryopreservation liquid |
JP7007686B2 (en) | 2017-03-08 | 2022-01-25 | 大日本住友製薬株式会社 | Manufacturing method of retinal pigment epithelial cells |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
EP3656842A1 (en) | 2017-03-31 | 2020-05-27 | Terumo BCT, Inc. | Cell expansion |
CA3070215A1 (en) | 2017-07-20 | 2019-01-24 | Riken | Method for maturation of retinal tissue containing continuous epithelium |
CA3070212A1 (en) | 2017-07-20 | 2019-01-24 | Riken | Method for preserving neural tissue |
JP7162221B2 (en) | 2017-09-08 | 2022-10-28 | 国立研究開発法人理化学研究所 | Cell aggregate containing retinal tissue and method for producing the same |
CN111094554A (en) | 2017-09-14 | 2020-05-01 | 国立研究开发法人理化学研究所 | Method for preparing retinal tissue |
WO2019054515A1 (en) | 2017-09-14 | 2019-03-21 | 国立研究開発法人理化学研究所 | Method for amplifying cone photoreceptors or rod photoreceptors using dorsalization signal transmitter or ventralization signal transmitter |
SG11202004829WA (en) | 2017-11-24 | 2020-06-29 | Sumitomo Chemical Co | Method for producing cell mass including pituitary tissue, and cell mass thereof |
WO2019103125A1 (en) | 2017-11-24 | 2019-05-31 | 住友化学株式会社 | Production method for cell mass including neural cells/tissue and non-neural epithelial tissue, and cell mass from same |
CA3096870A1 (en) | 2018-02-19 | 2019-08-22 | Sumitomo Dainippon Pharma Co., Ltd. | Cell aggregate, mixture of cell aggregates, and method for preparing same |
WO2020039732A1 (en) | 2018-08-24 | 2020-02-27 | 住友化学株式会社 | Cell aggregation including olfactory neuron or precursor cell thereof, and method for producing same |
CA3112902A1 (en) | 2018-09-28 | 2020-04-02 | Otsuka Pharmaceutical Factory, Inc. | Mammal cell preserving solution containing acarbose or stachyose |
EP3882342A4 (en) | 2018-11-15 | 2022-08-24 | JSR Corporation | Method for producing brain organoids |
TW202035683A (en) | 2018-12-20 | 2020-10-01 | 日商住友化學股份有限公司 | Embryonic erythroblast-containing cell population and method for producing same, cell culture composition, and compound test method |
EP3903789A4 (en) | 2018-12-28 | 2022-10-05 | Riken | Therapeutic drug for disease accompanied by disorders in retinal system cells or retinal tissue |
JP2022520722A (en) | 2019-01-23 | 2022-04-01 | アステリアス バイオセラピューティクス インコーポレイテッド | Dorsal-derived oligodendrocyte progenitor cells from human pluripotent stem cells |
JPWO2020184720A1 (en) | 2019-03-13 | 2020-09-17 | ||
WO2020218480A1 (en) | 2019-04-26 | 2020-10-29 | 国立研究開発法人理化学研究所 | Composite including neural retina, retinal pigment epithelial cells, and hydrogel, and method for producing same |
CN113728089A (en) | 2019-04-26 | 2021-11-30 | 株式会社大塚制药工场 | Trehalose-containing solution for preserving mammalian cells |
JPWO2021045217A1 (en) | 2019-09-06 | 2021-03-11 | ||
CA3162273A1 (en) | 2019-11-20 | 2021-05-27 | Sumitomo Pharma Co., Ltd. | Method for freezing cell aggregates |
WO2021100829A1 (en) | 2019-11-20 | 2021-05-27 | 大日本住友製薬株式会社 | Method for freezing neural cells |
US20230310614A1 (en) | 2020-09-11 | 2023-10-05 | Sumitomo Pharma Co., Ltd. | Medium for Tissue for Transplantation |
CN116157512A (en) | 2020-09-11 | 2023-05-23 | 国立研究开发法人理化学研究所 | Composite comprising cell aggregate containing neural retina and matrix, and method for producing same |
JPWO2022191216A1 (en) | 2021-03-09 | 2022-09-15 | ||
IL309344A (en) | 2021-06-17 | 2024-02-01 | Univ Kyoto | Method for producing cerebral cortical cell preparation derived from human pluripotent stem cells |
AU2022343749A1 (en) | 2021-09-13 | 2024-03-28 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of committed cardiac progenitor cells |
CA3232099A1 (en) | 2021-09-23 | 2023-03-30 | Adam Ezra Cohen | Genetically encoded voltage indicators and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5635386A (en) * | 1989-06-15 | 1997-06-03 | The Regents Of The University Of Michigan | Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture |
NZ314644A (en) * | 1993-05-24 | 2000-11-24 | Immunex Corp | Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue |
US5914268A (en) | 1994-11-21 | 1999-06-22 | National Jewish Center For Immunology & Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
WO1998007841A1 (en) | 1996-08-19 | 1998-02-26 | University Of Massachusetts | Embryonic or stem-like cell lines produced by cross species nuclear transplantation |
US6280718B1 (en) * | 1999-11-08 | 2001-08-28 | Wisconsin Alumni Reasearch Foundation | Hematopoietic differentiation of human pluripotent embryonic stem cells |
-
1999
- 1999-11-08 US US09/435,578 patent/US6280718B1/en not_active Expired - Lifetime
-
2000
- 2000-08-25 CN CNB008153264A patent/CN1228443C/en not_active Expired - Lifetime
- 2000-08-25 AU AU69404/00A patent/AU784928B2/en not_active Expired
- 2000-08-25 JP JP2001537473A patent/JP2003513664A/en active Pending
- 2000-08-25 KR KR1020027005890A patent/KR20030022766A/en not_active Application Discontinuation
- 2000-08-25 EP EP00957842A patent/EP1228194A1/en not_active Withdrawn
- 2000-08-25 IL IL14938700A patent/IL149387A0/en active IP Right Grant
- 2000-08-25 WO PCT/US2000/023469 patent/WO2001034776A1/en active IP Right Grant
- 2000-08-25 BR BR0015374-5A patent/BR0015374A/en not_active Application Discontinuation
- 2000-08-25 KR KR1020077008013A patent/KR20070047850A/en active Search and Examination
- 2000-08-25 CA CA002390281A patent/CA2390281C/en not_active Expired - Lifetime
-
2001
- 2001-08-27 US US09/940,175 patent/US6613568B2/en not_active Expired - Lifetime
-
2002
- 2002-04-28 IL IL149387A patent/IL149387A/en unknown
- 2002-05-03 SE SE0201328A patent/SE526490C2/en unknown
- 2002-05-06 IS IS6373A patent/IS6373A/en unknown
- 2002-05-07 NO NO20022180A patent/NO20022180L/en not_active Application Discontinuation
-
2003
- 2003-08-29 US US10/652,468 patent/US20040043484A1/en not_active Abandoned
-
2009
- 2009-10-01 JP JP2009229464A patent/JP2010042011A/en active Pending
-
2013
- 2013-10-07 JP JP2013210318A patent/JP2014000096A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2003513664A (en) | 2003-04-15 |
SE0201328D0 (en) | 2002-05-03 |
IL149387A0 (en) | 2002-11-10 |
IL149387A (en) | 2008-08-07 |
AU784928B2 (en) | 2006-07-27 |
US20020015694A1 (en) | 2002-02-07 |
CN1387565A (en) | 2002-12-25 |
CA2390281A1 (en) | 2001-05-17 |
KR20070047850A (en) | 2007-05-07 |
US6280718B1 (en) | 2001-08-28 |
NO20022180D0 (en) | 2002-05-07 |
BR0015374A (en) | 2002-12-24 |
SE0201328L (en) | 2002-07-05 |
CN1228443C (en) | 2005-11-23 |
KR20030022766A (en) | 2003-03-17 |
US20040043484A1 (en) | 2004-03-04 |
US6613568B2 (en) | 2003-09-02 |
SE526490C2 (en) | 2005-09-27 |
AU6940400A (en) | 2001-06-06 |
JP2010042011A (en) | 2010-02-25 |
EP1228194A1 (en) | 2002-08-07 |
IS6373A (en) | 2002-05-06 |
JP2014000096A (en) | 2014-01-09 |
WO2001034776A1 (en) | 2001-05-17 |
NO20022180L (en) | 2002-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2390281C (en) | Hematopoietic differentiation of human embryonic stem cells | |
US11261426B2 (en) | Pluripotent stem cell that can be isolated from body tissue | |
US20030153082A1 (en) | Hematopoietic cells from human embryonic stem cells | |
US9255249B2 (en) | Isolation and purification of hematopoietic stem cells from post-liposuction lipoaspirates | |
US20130064801A1 (en) | Cellular Compositions and Methods of Making and Using Them | |
JP2024026891A (en) | Methods and systems for producing hematopoietic lineage cells | |
US20050221482A1 (en) | Methods and compositions for obtaining hematopoietic stem cells derived from embryonic stem cells and uses thereof | |
JP2021535747A (en) | Generation of hematopoietic progenitor cells from human pluripotent stem cells | |
JPWO2008056779A1 (en) | Method for culturing and subculture of primate embryonic stem cells and method for inducing differentiation thereof | |
US20040110286A1 (en) | Method for making hematopoietic cells | |
CA2330208A1 (en) | Compositions and methods for use in affecting hematopoietic stem cell populations in mammals | |
Gordon-Keylock et al. | Induction of hematopoietic differentiation of mouse embryonic stem cells by an AGM-derived stromal cell line is not further enhanced by overexpression of HOXB4 | |
CN113557296A (en) | Expansion of hematopoietic stem cells | |
Schubbert et al. | Methods for PTEN in stem cells and cancer stem cells | |
Basak et al. | Human embryonic stem cells hemangioblast express HLA-antigens | |
US20230374458A1 (en) | Compositions and methods for generating human yolk sac-like hematopoietic cells | |
Kaufman et al. | Embryonic Stem Cells: Unique Potential to Treat Autoimmune Diseases | |
Kelley et al. | Collection and Expansion of Stem Cells | |
Kaufman et al. | Embryonicmaintainedlines, of yet human retain stem indefinitely embryonic (ES) their cells ability in are stem culture pluripotent to cells form as provides undifferentiated any cells cell a that new type. can model The cell | |
EP2749640A1 (en) | Processes for Producing Ectodermal, Mesodermal and Endodermal Cells as well as Pluripotent Stem Cells, Haematopoietic Stem Cells, Side Population Cells and Mesenchymal Stem Cells, and a Method of De-differentiating Peripheral Blood Cells | |
AU2016206280A1 (en) | Hematopoietic cells from human embryonic stem cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20200825 |